Search
Dogwood Therapeutics Inc
DWTXAdd to Watchlist
1.640USD
+0.060+3.80%
Close 07-31 16:00（ET）Quotes delayed by 15 min
54.78MMarket Cap
LossP/E TTM
More Details of Dogwood Therapeutics Inc Company
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Dogwood Therapeutics Inc Info
Ticker SymbolDWTX
Company nameDogwood Therapeutics Inc
IPO dateDec 17, 2020
CEODuncan (Gregory Scott)
Number of employees12
Security typeOrdinary Share
Fiscal year-endDec 17
Address44 Milton Avenue
CityALPHARETTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30009
Phone18666208655
Websitehttps://dwtx.com/
Ticker SymbolDWTX
IPO dateDec 17, 2020
CEODuncan (Gregory Scott)
Company Executives of Dogwood Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.30K
--
Dr. Abel De La Rosa, Ph.D.
Dr. Abel De La Rosa, Ph.D.
Independent Director
Independent Director
160.00
--
Ms. Angela Walsh
Ms. Angela Walsh
Chief Financial Officer
Chief Financial Officer
120.00
--
Dr. Richard James (Rich) Whitley, M.D.
Dr. Richard James (Rich) Whitley, M.D.
Independent Director
Independent Director
28.00
--
Mr. Alan Yu
Mr. Alan Yu
Director
Director
--
--
Mr. Melvin Toh
Mr. Melvin Toh
Director
Director
--
--
Mr. David (Rick) Keefer
Mr. David (Rick) Keefer
Independent Director
Independent Director
--
--
Mr. John C. Thomas, Jr.
Mr. John C. Thomas, Jr.
Independent Director
Independent Director
--
--
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ralph Grosswald
Mr. Ralph Grosswald
Senior Vice President - Operations
Senior Vice President - Operations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.30K
--
Dr. Abel De La Rosa, Ph.D.
Dr. Abel De La Rosa, Ph.D.
Independent Director
Independent Director
160.00
--
Ms. Angela Walsh
Ms. Angela Walsh
Chief Financial Officer
Chief Financial Officer
120.00
--
Dr. Richard James (Rich) Whitley, M.D.
Dr. Richard James (Rich) Whitley, M.D.
Independent Director
Independent Director
28.00
--
Mr. Alan Yu
Mr. Alan Yu
Director
Director
--
--
Mr. Melvin Toh
Mr. Melvin Toh
Director
Director
--
--
FAQs
Who are the top five shareholders of Dogwood Therapeutics Inc?
The top five shareholders of Dogwood Therapeutics Inc are: Mr. Gregory Scott (Greg) Duncan
How many institutions hold shares of Dogwood Therapeutics Inc (DWTX)?
As of 2026Q1, 40 institutions hold shares of Dogwood Therapeutics Inc, with a combined market value of approximately 3.70M, accounting for 11.07% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3615989.00.